CXCR7 antagonists

Patent metadata

Field	Value
Publication number	US-11059825-B2
Application number	US-201916379599-A
Country	US
Kind code	B2
Filing date	Apr 9, 2019
Priority date	Nov 29, 2012
Publication date	Jul 13, 2021
Grant date	Jul 13, 2021

Abstract

Compounds having formula I,

or pharmaceutically acceptable salts, hydrates or N-oxides thereof are provided and are useful for binding to CXCR7, and treating diseases that are dependent, at least in part, on CXCR7 activity. Accordingly, the present invention provides in further aspects, compositions containing one or more of the above-noted compounds in admixture with a pharmaceutically acceptable excipient.

First claim

What is claimed is:

1. A method of assaying a small organic molecule for CXCR7 antagonistic activity, said method comprising
(a) contacting the small organic molecule with cells expressing CXCR7 and a radioactive CXCR7 ligand to form a reaction mixture;
(b) aspirating the reaction mixture onto a PEI-treated GF/B glass filter;
(c) measuring the amount radioactivity remaining on the GF/B glass filter,
wherein said method comprises performing steps (a)-(c) with a positive control sample having a formula selected from the group consisting of

or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, wherein
R a is selected from the group consisting of hydrogen, hydroxyl, halogen, cyano, C 1-8 alkyl, C 1-8 alkoxy,C 1-8 haloalkyl, C 3-6 cycloalkyl, C 3-6 cycloalkylalkyl, amino, C 1-8 alkylamino, di C 1-8 alkylamino, carboxamide, carboxy C 1-4 alkyl ester, carboxylic acid, and —SO 2 —C 1-8 alkyl; and
R 2 is selected from the group consisting of H, halogen, CN, C 1-8 alkyl, C 1-8 haloalkyl, C 1-8 hydroxyalkyl, —OR a , —CO 2 R a , —X—CO 2 R a , —NR a R b , —CONR a R b and —X—CONR a R b .

2. The method of claim 1 , wherein said cells expressing CXCR7 are MCF-7 or MDA-MB435S cells or isolated human monocytes.

3. The method of claim 1 , wherein said radioactive CXCR7 ligand is SDF-1, I-TAC, or a combination thereof.

4. The method of claim 1 , wherein step (a) further comprises a binding buffer.

5. The method of claim 4 , wherein the binding buffer comprises 25 mM HEPES, 140 mM NaCl, 1 mM CaCl 2 , 5 mM MgCl 2 and 0.2% bovine serum albumin, at pH 7.1.

6. The method of claim 1 , further comprising washing the PEI-treated GF/B glass filter after step (b) with a wash buffer.

7. The method of claim 1 , wherein the wash buffer comprises 25 mM Hepes, 140 mM NaCl, 1 mM CaCl 2 , 5 mM MgCl 2 , at pH 7.1.

8. The method of claim 1 , wherein said measuring comprises adding scintillation fluid to the aspirated and washed GF/C glass filter.

9. The method of claim 1 , wherein R a is selected from the group consisting of selected from the group consisting of hydrogen, halogen, cyano, C 1-8 alkyl and —SO 2 —C 1-8 alkyl.

10. The method of claim 1 , wherein R 2 is selected from the group consisting of H and C 1-4 alkyl.

11. The method of claim 1 , wherein R a is selected from the group consisting of hydrogen, halogen, cyano, C 1-8 alkyl and —SO 2 —C 1-8 alkyl; and R 2 is selected from the group consisting of H and C 1-4 alkyl.

Assignees

• Chemocentryx Inc

Inventors

• Fan Junfa
• Krasinski Antoni
• Lange Christopher W
• Lui Rebecca M
• Mcmahon Jeffrey P
• Powers Jay P
• Zeng Yibin
• Zhang Penglie

Classifications

• G01N33/5759

  involving compounds localised on the membrane of tumour or cancer cells · CPC title

• C07D487/04 Primary

  Ortho-condensed systems · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• G01N2333/7158

  for chemokines · CPC title